Why the study?
Implantable cardiac monitors often have a high false-positive alert rate that increases clinic workload. The real-world diagnostic performance, transmission burden, and impact of remote reprogramming for the LUX-Dx ICM needed evaluation across all detectable arrhythmias.
Population
133 consecutive patients receiving a LUX-Dx ICM between July 2023 and October 2024
Comparison
LUX-Dx ICM performance before vs after remote reprogramming
Design
Single-center retrospective observational study
Follow-up
Median 13-month follow-up
Answers are grounded in this paper and cite their sources.
LUX-Dx ICM performance data may ease device clinic workload; leaves open need for randomized trials before practice change.
Background Implantable cardiac monitors (ICMs) are widely used for long-term arrhythmia surveillance but are often limited by a high false-positive alert rate, increasing the workload for device clinics. The LUX-Dx™ ICM incorporates dual-stage detection algorithms and remote reprogramming features designed to improve diagnostic accuracy and workflow efficiency. Objective To assess the real-world performance of the LUX-Dx™ ICM across all detectable arrhythmias, evaluating positive predictive value (PPV), transmission burden, and the impact of remote reprogramming. Methods We retrospectively analyzed 133 consecutive patients who received a LUX-Dx™ ICM between July 2023 and October 2024 with follow-up data collected through June 2025. Device episodes and transmissions were reviewed over a median 13-month follow-up. PPV was calculated at both patient- and episode-levels. Changes in PPV before and after remote reprogramming were also assessed. Results A total of 55,064 episodes and 5,192 transmissions were recorded (4.0 episodes and 1.2 transmissions per patient-month). Overall patient-level PPV was 87% (110/126), highest for bradycardia (100%) and lowest for pauses (71%). Overall, 93 of 126 patients (74%) with adjudicated episodes had at least one false-positive detection during follow-up. Episode-level PPV was 82% (95% CI: 82−83). Remote reprogramming was performed in 34% of patients and was associated with a descriptive increase in episode-level PPV (from 77% to 87%). Review strategies focusing on the first, longest, or fastest episode per transmission yielded comparable PPVs. Conclusions In routine clinical practice, the LUX-Dx™ ICM demonstrated favorable positive predictive value. Remote reprogramming enabled individualized optimization of detection parameters, although its potential impact on detection performance requires further investigation.
No takes yet. Share an insight, caveat, or question.
Fareh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: